On November 10, 2016, Anthera released that "the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks." Then on December 27, 2016, Anthera made public that its SOLUTION Phase 3 Study for liprotamase also failed to meet its primary endpoint and Anthera said it would conduct a new liprotamase study. During this time, Anthera stock dropped 73%, from a previous close on November 9, 2016 of $2.78 per share to a close of $0.74 per share on December 28, 2016.
If you are aware of any facts relating to this investigation, or purchased Anthera shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/anth. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-anthera-pharmaceuticals-inc-anth-300391195.html
SOURCE Bronstein, Gewirtz & Grossman, LLC